Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Cholangiocarcinoma 6Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Miscellaneous 1Solid Tumor 1Sarcoma 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Digestive System Neoplasms 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1

Interventions

toripalimab 1sintilimab 1pemigatinib 1Vinorelbine 1Platinum Compounds 1Nivolumab 1Ipilimumab 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Non Small Cell Lung Cancer × pemigatinib × Clear all
NCT05004974 2024-03-12

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Phase 2 Unknown
20 enrolled
Thoracic

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡